LyrArc Article Gist
Biotech firm CureVac is developing a vaccine for coronavirus that should be available by fall 2020. It hopes to develop the vaccine using mRNA (messenger ribonucleic acid) as a source of information. Managing director of Hopp Biotech the holding company for CureVac, says mRNA has several advantages, including one related to a vaccine developed by CureVac for rabies. He says 1 microgram could suffice to vaccinate 1 million people because it is very potent, and because it can be mass produced quickly.

LyrArc Article Gist
Murali Krishnan of DW.com has this interview with Adar Poonavalla of Serum Institute of India the largest vaccine maker in the world that makes about 60% of all vaccines used in the world. It is beginning manufacturing of the Oxford vaccine so that the manufacturing process is ready to turn out a billion vaccine doses over a short period of 1 to 2 years. Serum's Oxford vaccine would be priced at $13 per dose for coronavirus. Serum is conducting its own trials for the vaccine. About 40 million doses would be ready by October. 

India's pioneering work in vaccine production on a large scale is one of the reasons the world can tackle the future with some confidence for the economy and the health of billions of people all over the world.

LyrArc Article Gist
The lack of vaccine supplies in Africa and Latin America, parts of Asia, is a major problem in 2021. Of the 66 million doses of vaccine planned to be given to Africa under COVAX plan only 19 million have been delivered. In total about 49 million doses have been delivered. Vaccine shortages are a result of the huge wave of coronavirus in India in April, so that vaccine shipments from India have stalled. Of the countries in Africa a few have made some progress- Egypt, Ghana, Nigeria. Other problems in Africa are lack of trained people to give vaccination. Last week 2.3 billion dollars in additional funds were raised at a donor conference for COVAX, the initiative for poor countries vaccines. That is enough to buy 1.8 billion doses. US and UK have not exported vaccines. India has made a good start in shipping vaccines to many countries in Africa, Asia and Latin America as shown in the Ministry of External Affairs website of the Indian government. For India to do this once it meets its own needs and resume exports, vaccine patent protection needs to be lifted for sometime, which the US is now accepting. ...

LyrArc Article Gist
Encouraging early results for a vaccine from Moderna Inc. which tested on a small group of 8 healthy humans. A key requirement that the neutralizing antibodies created by the vaccine stop the coronavirus from replicating was met in the vaccine developed by Moderna. A larger human trial will now proceed for hundreds of healthy people. In July another trial will have thousands of healthy people. By the end of the year the company plans to make millions of vaccines.

LyrArc Article Gist
The coronavirus pandemic death toll reaches 700,000 making it the deadliest in history. In 2021 the death toll increased with another wave now in the southern and western states such as Florida, Texas in the south, and California, Idaho in the west, with deaths concentrated among the unvaccinated.

The vaccination drive stalled by August 2021 leaving a large number of people between 18-35 unvaccinated mostly in the south and some in western states. States with large Republican support tended to show higher vaccination resistance though the reasons for not getting vaccinated were complex and some misinformation played apart in fear of vaccines. Vaccine supplies were ample in the US.

LyrArc Article Gist
How is it that Britain's regulatory agency approved the Pfizer vaccine before the U.S. FDA agency? This report in the NYT says FDA looks at the raw data. Britain's Medicine and Healthcare Products Regulatory Agency looks at the information provided by the company. It still does the testing batch by batch and has access to the data and looks at thousands of pages of data. What about the European Union? The European Union Medicines Agency meets on December 29. It takes days after it meets to get input of 27 countries so that vaccination cannot start till January. The U.S. president summoned the FDA to the White House to find out how soon the FDA could act. Both Britain and the U.S. are feeling the impact of the second wave of coronavirus.

LyrArc Article Gist
The death toll from coronavirus reaches 200,000 in Mexico, the third highest after the US and Brazil. Vaccine supplies are low in Europe affecting the vaccination drive. 

LyrArc Article Gist
The true story of the two German scientists, children of immigrants from Germany, who did the research behind the Pfizer vaccine for coronavirus. One the son of a guest worker from Turkey who worked at a car factory in Cologne, another the daughter of a doctor who finished medical school and immigrated to Germany. They started primarily on cancer vaccines using new mRNA technologies. Much of their work focused on meeting the gap that had developed says Ozlem Tureci, between what was done in the labs and what was available to patients and doctors. 

LyrArc Article Gist
The Oxford vaccine through testing in South Africa, the Moderna vaccine through testing in the U.S., the German vaccine through testing in the U.S., and Indian vaccine, are all racing towards completion by November 2020 or earlier.

LyrArc Article Gist
The UK and the European Union compete for limited vaccine supplies as a plant in Belgium has production problems and Astra Zeneca says it can only supply half of what it promised to Europe.

LyrArc Article Gist
Moderna, J&J, Pfizer in the U.S., Sanofi in France, AstraZeneca in Britain, have accelerated their efforts to have a vaccine ready by the fall.  Moderna and Pfizer use new technologies. Astra Zeneca is working with Oxford University on a vaccine that builds on existing technologies. Both AstraZeneca and Sanofi are building capacity to make hundreds of millions of doses of the vaccine. 

LyrArc Article Gist
Japan is staying ahead in vaccine development with 5 vaccines under development including 1 MrNA vaccine. Vaccine makers using Japanese research are Shionogi, Anges, Daiichi Sankyo, KM Biologics, ID Pharm. Shoionogi also announced in May that it is working on vaccine for variants of coronavirus. Japanese vaccines were recently sent to Taiwan.

LyrArc Article Gist
The experience of J&J and Novavax in vaccine manufacturing shows the importance of vaccine manufacturing and of Quality Assurance in the production of vaccines for coronavirus. The success of Pfizer and Indian companies in vaccine manufacturing shows how important it is to think early and plan early for vaccine manufacturing technologies, personnel and quality assurance. This is also why the US effort, India's billion vaccine target in 6-12 months of planning, is a great effort in thinking ahead of every aspect of vaccines and vaccinating, planning of all details, hard work, by Pfizer, by Indian pharmaceutical companies, and by the Modi and Biden administrations. 

LyrArc Article Gist
Serum Institute in India's vaccine developed with Oxford University is a leading one of the 6 candidates in India for coronavirus vaccine. It is expected to be ready by September. ICMR also has a vaccine that could be ready by India's Independence Day of August 15. One of the vaccines is for the elderly. Serum Institute has the advantage of being one of the leading manufacturers of vaccines in the world. India makes 60% of the world's vaccines giving it much experience in manufacturing that is needed today.

LyrArc Article Gist
The U.S. is moving quickly to gain access to an effective vaccine by September or October 2020. It is doing this by providing the money for companies to conduct trials and ramp up manufacturing in a big way. The U.S. government has agreed to give Astra Zeneca upto $1.2 billion to secure supply of a Oxford University developed vaccine which could be ready by October. Astra Zeneca has agreed to make the vaccine under a licensing deal with Oxford University's Jenner Institute and promised it will not make a profit on this. U.S. has also given $483 million to Moderna in Cambridge, Massachusetts, for making the vaccine. Both Oxford and Moderna are testing the vaccine on humans. Oxford uses a tested older technology, Moderna a new technology. UK has given Astra Zeneca $79 million to secure 100 million doses of the vaccine, with 30 million ready by September. Oxford is also in negotiations with Gavi the international vaccine alliance, and Coalition for Epidemic Preparedness Innovations on further deals to boost production. Oxford began a 1100 person study in April, and is  doing a 5000 person trial in late May.  ...